Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 3—March 2011

Letter

Mycobacterium mageritense Pulmonary Disease in Patient with Compromised Immune System

R. Gordon HuthComments to Author , Barbara A. Brown-Elliott, and Richard J. Wallace
Author affiliations: Author affiliations: University of Texas Southwestern Residency Programs, Austin, Texas, USA (R.G. Huth); University of Texas Health Science Center, Tyler, Texas, USA (B.A. Brown-Elliott, R.J. Wallace, Jr.)

Main Article

Table

In vitro activity of 23 isolates of Mycobacterium mageritense, United States, 2009*

Antimicrobial agent
No. isolates tested
MICs of current isolate, μg/mL
Intermediate breakpoint, μg/mL
MIC range, μg/mL
MIC50, μg/mL
MIC90, μg/mL
% S/I
Amikacin 23 8 32 <1–32 16 32 100
Cefoxitin 23 16 32–64 <8–256 32 64 91
Ciprofloxacin 23 0.25 2 <0.25–0.5 0.25 0.5 100
Clarithromycin† 23 8 4 1–>64 >32 >64 4
Doxycycline 22 1 2–8 0.25–>64 8 >32 50
Imipenem 22 4 8 <0.5–8 2 4 100
Linezolid 22 4 16 <2–16 4 8 100
Sulfamethoxazole 21 4 32 <2–32 8 32 100
Trimethoprim/sulfamethoxazole 6 1/19 2/38‡ <0.25/4.8– 2/38 0.5/9.5 2/38 100
Tobramycin 23 <2 8 2–64 >16 >32 30
Tigecycline 5 0.12 –§ <0.03–0.12 0.06 0.12 NA

*Includes 6 isolates previously reported (2). S, susceptible; I, intermediate; NA, not available.
†Three days’ incubation.
‡Proposed breakpoint (7).
§No Clinical and Laboratory Standards Institute breakpoints established for tigecycline.

Main Article

TOP